3D Tissue Models

View Profile


Peer Reviewed Papers, Books, Chapters

Year Title Citation Authors Review type Summary Keywords File filename File mime type
1. 2010 Improvement of Skin Scarless Wound Healing With Histidine-Lysine Polymer Enhanced siRNA Delivery NA
2. 2009 Overcome Delivery Hurdles for Realizing Therapeutics Promise of siRNA and miRNA. AAPS Journal, invited review.
3. 2009 Treatment of Angiogenesis Diseases Using Nanoparticle Formulations Molecular Therapy
4. 2009 Advances in Systemic siRNA Delivery Drugs of the Future. 2009, 34(9).
5. 2009 Leveraging Therapeutic Potential of Multi-targeted siRNA Inhibitors Future Medicinal Chemistry, 2009, 1 (9)
6. 2009 Pulmonary Delivery of Small Interfering RNA for Novel Therapeutics Delivery Technologies for Biopharmaceuticals, John Wiley & Sons, Ltd. England
7. 2009 The Modulation of Ischemia / Reperfusion injury in experimental renal transplantation by nanoparticle packaging of siRNA Transplantation
8. 2008 Delivering small interfering RNA for novel therapeutics Book chapter in “Drug Delivery Systems”. Humana press. Methods Mol Biol. 2008; 437:93-107
9. 2008 Systemic delivery of HK Raf -1siRNA Polyplexes Inhibits MDA-MB-435 Xenografts Cancer Gene Therapy. 2008, 1-11
10. 2008 The Human Rhomboid Family-1 Gene RHBDF1 Is Essential to Cancer Cells Survival and Critical in EGFR Activation. Molecular Cancer Therapeutics, 2008; 7(6):1355-64..
11. 2008 Application of siRNA against SARS in the Rhesus Macaque Model. Book chapter, "siRNA, shRNA and miRNA Protocols" Methods Mol Biol. 2008; 442:139-58
12. 2006 Harnessing in vivo siRNA delivery for functional genomics and novel therapeutics. Drug Discovery Today, Vol. 11, 67-74
13. 2005 In vivo application of RNA interference: from functional genomics to therapeutics. Adv Genet. 54:117-42
14. 2005 Using siRNA in prophylactic and therapeutic regimens against SARS coronavirus in Rhesus macaque Nature Medicine. 11(9) 944-951
15. 2005 Transporting silence: Design of carriers for siRNA to angiogenic endothelium J Control Release. 109(1-3):5-14
16. 2005 Modulation of Angiogenesis Pathway Using siRNA for Gene Function Validation and Novel Therapeutics. Trend in Mol. Medicine. Vol.11 No.3
17. 2004 Delivering siRNA in vivo for functional genomics and novel therapeutics RNA Interference Technology. Cambridge University Press. P.303-317
18. 2004 Inhibition of ocular angiogenesis by siRNA targeting vascular endothelial growth factor-pathway genes; therapeutic strategy for herpetic stromal keratitis American Journal of Pathology, 165(6), 2177-2184
19. 2004 Cancer siRNA Therapy by Tumor Selective Delivery With Ligand-Targeted Sterically-Stabilized Nanoparticle Nucleic Acid Research, Vol. 32, No.19
20. 2004 Delivering siRNA to Animal Disease Models for Validation of Novel Drug Targets In Vivo PharmaGenomics, July/August 2004, P. 28-38
21. 2004 Prophylactic and therapeutic effects of small interfering RNA targeting SARS-coronavirus. Antiviral Therapy. 9:365-374
22. 2003 SiRNA-Mediated Antitumorigenesis For Drug Target Validation And Therapeutics Current Opinion in Molecular Therapeutics, 5(3): 225-234
23. 2003 From Correlation to Causation to Control: Utilizing Preclinical Disease Models to Improve Cancer Target Discovery Preclinica, 1(1): 31-42
24. 1999 Molecular Evaluation Of Biopsy And Autopsy Specimens From Patients Receiving In Vivo Retroviral Gene Therapy. Hum Gene Therapy. 20;10(5):733-40
25. 1999 Distribution Of Retroviral Vectors And Vector Producer Cells Using Two Routes Of Administration In Rats. Gene Therapy.6, 1389-1396.
26. 1997 Adenovirus - Mediated Transduction Of Ribozymes Abrogates Her-2 /Neu And Pleiotrophin Expression And Inhibits Tumor Cell Proliferation Gene Therapy, 4:934-949
27. 1996 Safety Of Adenovirus-Mediated Transfer Of The Human Cystic Fibrosis Transmembrane Conductance Regulator Cdna To The Lungs Of Nonhuman Primates Human Gene Therapy. 7:301-318
28. 1994 The Human DNA Binding Protein, Po-Ga, Is Homologous To The Large Subunit Of Mouse Replication Factor C And Potentially Regulated By Alternate 3' Processing Of Its Mrna. Gene Vol.57, No.3, P. 123-128
29. 1994 Identification Of A Putative Alternate Sigma Factor And Characterization Of A Multicomponent Regulatory Cascade Controlling The Expression Of Pseudomonas Syringae Pv. Syringae Pss61 Hrpand Hrma Genes Jour. of Bacteriology, 176. 1025-1036
30. 1993 Characterization of the Pseudomonas syringae pv. syringae 61 hrpJ and hrpI genes: homology of HrpI to a superfamily of proteins associated with protein translocation Mol Plant Microbe Interact., 6(4):515-20
31. 1993 Cloning And Expression Of A Novel DNA Binding Protein: Po-Ga Biochemistry and Biophysics Research Communication. 192(2), 779-786
32. 1992 Organization and environmental regulation of the Pseudomonas syringae pv. syringae 61 hrp cluster J Bacteriol. 174(6):1734-41
33. 1992 A Heparin‑Binding Growth Factor Secreted From Breast Cancer Cellshomologous To A Developmentally Regulated Cytokine Journal of Biological Chemistry, Vol.267, No.4, p.2582-2587
34. 1991 Proopiomelanocortin Gene Promoter Elements Required For Constitutive And Glucocorticoid-Repressed Transcription Molecular Endocrinology, 5(12)1973-1982
35. The poor prognosis of esophageal squamous cell carcinoma (ESCC) emphasizes the urgent need to better understand the carcinogenesis and develop prevention strategies. Pubmed The poor prognosis of esophageal squamous cell carcinoma (ESCC) emphasizes the urgent need to better understand the carcinogenesis and develop prevention strategies. Previous studies have highlighted the potential of using Vitamin E (tocopherols) for cancer chemoprevention, but the preventive activity of α-Tocopherol against ESCC remains to be elucidated. Our data showed that early-stage supplementation with α-Tocopherol significantly prevented esophageal carcinogenesis induced by N-nitrosomethylbenzylamine (NMBA) in ESCC rat model. In the Het-1A cell model, α-Tocopherol markedly suppressed cell proliferation, promoted cell cycle G2-phase arrest and increased apoptosis. Gene microarray and proteins array analysis indicated that Akt signaling was a potential target for α-Tocopherol. We further demonstrated that α-Tocopherol increased the expression of PPARγ and its downstream tumor suppressor PTEN. Knockdown of PPARγ activated Akt signaling transduction, whereas this process was attenuated by the presence of α-Tocopherol and PPARγ agonist Rosiglitazone. In contrast, the effect of α-Tocopherol on Akt inhibition was not observed in established tumors, neither in cancerous cell lines which constitutively expressed higher levels of PPARγ. These results were closely correlated with the ineffectiveness of α-Tocopherol in the late stage of ESCC carcinogenesis. Taken together, our study suggested that α-Tocopherol may serve as a PPARγ agonist for the chemoprevention of esophageal cancer. Akt; PPARγ; esophageal cancer; tocopherol; vitamin E


About Us | Privacy Policy | Site Map | FAQs | Advertise With Us | Community
BiotechScienceNews.com promotes research and ranks life scientists working in the life science spectrum involving biotechnology,
drug discovery, genomics, microbiology, neuroscience, medicine, pharmacology, cell biology, and molecular biology.